LENSAR, Inc.

LENSAR, Inc. is a medical device company based in Orlando, Florida, founded in 2004. The company specializes in designing and marketing advanced laser systems for cataract treatment and corneal astigmatism management. LENSAR is recognized for its pioneering work in femtosecond laser technology, which enhances surgical outcomes through proprietary imaging and precise procedure planning. The company's flagship products include the LENSAR Laser System, which assists surgeons with detailed imaging and planning, and the ALLY Robotic Cataract Laser System, cleared by the FDA in 2022. The ALLY system combines robotic intelligence with surgeon precision, improving efficiency and reducing procedure times. LENSAR's technology aims to enhance the management of astigmatism during cataract procedures, serving ophthalmic surgeons and surgical centers focused on advanced laser-assisted solutions. LENSAR is publicly traded on NASDAQ under the ticker symbol LNSR and has shown financial growth, with projected revenues of approximately $45.7–46.0 million for 2024. The company is set to expand its reach through a merger agreement with Alcon, a leader in ophthalmic surgical products.

• Employees 140
• Founded 2004
• Annual Revenue $57065000
• Total Funding $149000000